logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
L

Liangzhi Xie

Beijing Engineering Research Center of Protein and Antibody
H指数:20
被引数:1,666

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

奋尼妥利单抗联合SCT200治疗复发或转移性头颈部鳞状细胞癌的Ib期临床试验

Cancer Medicine
IF3.1
2026-09-300
OAAI
Jinguan Lin; Song Qu; Kunyu Yang; Tao Zhang; Yuansong Bai; Jian Wu; Yanjing Huang; Meiyu Fang; Xianling Liu; Xiaoming Huang; Nianyong Chen; Zhendong Li; Weidong Li; Songnan Zhang; Shurong Zhang; Guangyuan Hu; Yan Sun; Xiaohong Chen; Yanyan Liu; Shanghua Jing; Liangfang Shen; Zhiwei Chang; Liangzhi Xie; Wenlin Gai; Yan Wang; Xinyue Chen; Dongfang Liu; Ye Guo
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Finotonlimab (PD-1抑制剂) 联合贝伐单抗 (贝伐单抗生物仿制药) 作为晚期肝细胞癌的一线治疗: 一项随机2/3期试验

Signal Transduction and Targeted Therapy
IF52.7
2025-08-060
OAAI
Chuanhua Zhao; Yanqiao Zhang; Gang Wang; Jinfang Zheng; Weiqing Chen; Zheng Lu; Li Zhuang; Shanzhi Gu; Lei Han; Zhendong Zheng; Zujiang Yu; Yongsheng Yang; Hongmei Sun; Xiaoyong Wei; Ying Cheng; Hailan Lin; Bo Zhu; Guicheng Wu; Kaijian Lei; Wei Wang; Yuwen Wang; Kehe Chen; Ximing Xu; Cuiping Zheng; Yanzhi Bi; Sijuan Ding; Jingdong Zhang; Wei Li; Hailong Liu; Jun Wang; Xianling Liu; Yangfeng Du; Lianming Cai; Jingran Wang; Zhanxiong Luo; Baocai Xing; Jie Shen; Lin Yang; Jianbing Wu; Ou Jiang; Zhigang Peng; Xiuli Liu; Bangwei Cao; Liangfang Shen; Aibing Xu; Aimin Li; Shaojun Chen; Ting Fu; Jian Chen; Chuan Jin; Lei Zhang; Jun Lv; Chengwu Zhang; Xiaoman Zhang; Yu Wang; Huo Su; Qiang Zhou; Wenlin Gai; Liangzhi Xie; Jianming Xu
Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial

finotonlimab联合多西他赛对比多西他赛治疗既往经治的晚期鳞状细胞非小细胞肺癌的疗效与安全性：一项随机、双盲、III期临床试验

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-04-010
OA
Han, Baohui; Wu, Lin; Yang, Runxiang; Wu, Hongbo; Li, Wei; Yu, Yan; Zhang, Mingjuan; Sun, Hongmei; Chu, Tianqing; Zhong, Fukuan; Fang, Yong; Wu, Rong; Bian, Tao; Guo, Xiaoqing; Sun, Meili; Zhang, Yanming; Liu, Lianke; Liu, Xuewen; Pan, Yueyin; Jiang, Ou; Wei, Zonghui; Lin, Haifeng; Guo, Wei; Fang, Jian; Wang, Jialei; Ding, Cuimin; Hu, Yanping; Ye, Feng; Zhuang, Wu; Ye, Shucheng; Wang, Lihong; Huang, Zhe; Liu, Chang; Yang, Ling; Wang, Jinling; Xie, Liangzhi
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants

双价蛋白COVID-19疫苗SCTV01C对抗原匹配和不匹配变体的持续免疫原性

EXPERT REVIEW OF VACCINES
IF4.8
2025-01-270
OA
Wang, Guiqiang; Zhao, Kexin; Zhao, Xiuli; Cui, Yimin; He, Peng; Zhang, Tianzuo; Wang, Yanchao; Shi, Rui; Li, Yanhua; Wang, Qian; Ren, Yanping; Chen, Zhisong; Zhao, Xuedan; Xie, Zekang; Liang, Yufei; Tian, Qingyun; Pan, Jing; Zhang, Chao; Han, Ying; Dai, Yuyang; Ni, Siyang; Zhang, Yun; Yang, Xinjie; Fu, Yongpan; Liu, Dongfang; Li, Jing; Zhang, Miaomiao; Hu, Zhongyu; Xie, Liangzhi
Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial

四价重组新型冠状病毒肺炎蛋白疫苗SCTV01E在3至17岁儿童和青少年中的安全性和免疫原性: 一项随机，双盲，安慰剂对照的2期临床试验

VACCINES
IF3.4
2025-01-070
OAAI
Zhu, Fengcai; Huang, Ting; Jin, Pengfei; Zhang, Linglin; Jin, Zhongqiang; Zhang, Wenli; Yuan, Dongya; Wang, Zhong; Deng, Yusong; Li, Jiaxin; Shen, Xiao; Fu, Yongpan; Li, Jian; Yang, Xinjie; Li, Jing; Xie, Liangzhi
Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial

中剂量免疫耐受诱导方案相较于低剂量方案，具有更快的达标速度、更少的出血事件且不增加医疗成本：一项多中心随机对照临床试验

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
IF3.4
2025-01-010
OAAI
Li, Zhengping; Li, Zekun; Cheng, Xiaoling; Zhang, Heng; Yang, Can; Xu, Qian; Chen, Zhenping; Zhen, Yingzi; Li, Gang; Liu, Guoqing; Yao, Wanru; Zhou, Min; Jin, Jiao; Huang, Jie; Fang, Yongjun; Xie, Liangzhi; Poon, Man-Chiu; Wu, Runhui
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study
ADVANCES IN THERAPY
IF4
2024-09-040
PRE
Cheng, Ying; Pan, Zhanyu; Wu, Lin; Zhu, Bo; Yu, Yan; Zang, Kai; Zhuang, Wu; Liu, Lianke; Gu, Kangsheng; Lian, Juanwen; Chen, Rixin; Bian, Tao; Lin, Dang; Sun, Shenghua; Li, Wei; Hang, Xiaosheng; Jiang, Ou; Zhong, Fukuan; Wang, Rui; Luo, Hui; Shi, Huaqiu; Wei, Zonghui; Zhao, Li; Chen, Shaoshui; Sun, Hongmei; Li, Xingya; Sun, Debin; Ren, Tiejun; Lei, Kaijian; He, Miao; Li, Gaofeng; Liu, Hailong; Li, Runpu; Hu, Chunhong; Kong, Li; Sun, Meili; Xie, Liangzhi; Gai, Wenlin; Chen, Weiqiu; Huang, Zhe; Ren, Wenwen; Su, Huo
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial
NATURE COMMUNICATIONS
IF15.7
2024-07-240
OAAI
Zhang, Ruizhi; Zhao, Junshi; Zhu, Xiaoping; Guan, Qinghu; Liu, Shujun; Li, Meihong; Gao, Jianghua; Tan, Jie; Cao, Feng; Gan, Beifang; Wu, Bo; Bai, Jin; Liu, Youquan; Xie, Gang; Liu, Chi; Zhao, Wei; Yan, Lixin; Xu, Shuping; Qian, Gui; Liu, Dongfang; Li, Jian; Li, Wei; Tian, Xuxin; Wang, Jinling; Wang, Shanshan; Li, Dongyang; Li, Jing; Jiao, Yuhuan; Li, Xuefeng; Chen, Yuanxin; Wang, Yang; Gai, Wenlin; Zhou, Qiang; Xie, Liangzhi
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial

Finotonlimab联合化疗治疗复发或转移性头颈癌: 一项随机3期试验

NATURE MEDICINE
IF50
2024-06-280
PRE
Shi, Yuankai; Guo, Wei; Wang, Wei; Wu, Yunteng; Fang, Meiyu; Huang, Xiaoming; Han, Ping; Zhang, Qingyuan; Dong, Pin; Zhou, Xiaohong; Peng, Hanwei; Hu, Chunhong; Chen, Xiaopin; Zhang, Shurong; Chang, Zhiwei; Li, Xiaojiang; Ding, Yuhai; Qu, Song; Jing, Shanghua; Zhang, Songnan; Gui, Lin; Sun, Yan; Wang, Lin; Liu, Yanyan; Wu, Hui; Li, Guoqing; Fu, Zhichao; Shi, Jianhua; Jiang, Hao; Bai, Yuansong; Cui, Jiuwei; Zheng, Yulong; Cui, Wei; Jia, Xiaojing; Zhai, Limin; Cai, Qingqing; Xiong, Deming; Wu, Yunong; Cao, Junning; Wu, Rong; Hu, Guangyuan; Peng, Liang; Xie, Liangzhi; Gai, Wenlin; Wang, Yan; Su, Yuehua

研究方向

暂未获取到该数据
W
Wenlin Gai
H 指数:8论文数:38被引数:200
李健 封面图
李健
H 指数:58论文数:679被引数:1.7万
S
Suad Hannawi
H 指数:21论文数:166被引数:1,443
A
Ahmad Alamadi
H 指数:4论文数:11被引数:90
Y
Yuanxin Chen
H 指数:21论文数:59被引数:2,575
A
Alaa Abuquta
H 指数:5论文数:18被引数:94
S
Sally Mahmoud
H 指数:14论文数:49被引数:1,448
D
Dan Meng
H 指数:35论文数:154被引数:4,178
X
Xuefeng Li
H 指数:13论文数:75被引数:573
C
Chunyun Sun
H 指数:12论文数:34被引数:520